G82S RAGE polymorphism is associated with Alzheimer's disease

Area of Science:

• Neuroscience
• Genetics
• Immunology

Background:

• Receptor for advanced glycation end products (RAGE) plays a role in Alzheimer's disease (AD) pathophysiology.
• RAGE interacts with amyloid beta (Aβ) and promotes inflammation.
• Soluble RAGE (sRAGE), a RAGE splice variant, acts as a decoy receptor for Aβ.

Purpose of the Study:

• To investigate the G82S RAGE polymorphism in Alzheimer's disease.
• To determine the association between this polymorphism and sRAGE expression, total RAGE (tRAGE), and Aβ load.

Main Methods:

• Genotyping for the G82S RAGE polymorphism.
• Quantification of sRAGE, tRAGE, and TNF-α expression.
• Assessment of amyloid beta peptide (Aβ) load.

Main Results:

• The heterozygous (GS) genotype was more prevalent in AD patients compared to the wild (GG) genotype.
• AD patients exhibited decreased sRAGE expression.
• AD patients showed increased tRAGE and TNF-α expression.

Conclusions:

• The G82S RAGE polymorphism is significantly associated with Alzheimer's disease development.
• This polymorphism correlates with altered expression of sRAGE, tRAGE, and TNF-α in AD.
• These findings suggest a genetic link between RAGE pathway dysregulation and AD pathogenesis.